scholarly journals Intravitreal Ranibizumab Treatment in Macular Edema Secondary to Central Retinal Vein Occlusion

2019 ◽  
pp. 26-28
Keyword(s):  
Macular Edema ◽  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
Current Treatment ◽  
Intravitreal Ranibizumab ◽  
Vascular Growth ◽  
Vein Occlusion ◽  
Vascular Growth Factor ◽  
Central Retinal Vein ◽  
Ranibizumab Treatment

The two main complications of central retinal vein occlusion are macular edema and neovascularizations. Intravitreal anti-vascular growth factor and corticosteroid injections are the mainstays of the current treatment of central retinal vein occlusion. In this review, we aimed to summarize the clinical studies of intravitreal ranibizumab in macular edema secondary to central retinal vein occlusion.

Intravitreal Ranibizumab Treatment in Macular Edema Secondary to Central Retinal Vein Occlusion

2019 ◽  
pp. 26-28
Keyword(s):  
Macular Edema ◽  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
Current Treatment ◽  
Intravitreal Ranibizumab ◽  
Vascular Growth ◽  
Vein Occlusion ◽  
Vascular Growth Factor ◽  
Central Retinal Vein ◽  
Ranibizumab Treatment

The two main complications of central retinal vein occlusion are macular edema and neovascularizations. Intravitreal anti-vascular growth factor and corticosteroid injections are the mainstays of the current treatment of central retinal vein occlusion. In this review, we aimed to summarize the clinical studies of intravitreal ranibizumab in macular edema secondary to central retinal vein occlusion.

scholarly journals Intravitreal Ranibizumab Treatment in Macular Edema Secondary to Central Retinal Vein Occlusion

2019 ◽  
pp. 26-28
Keyword(s):  
Macular Edema ◽  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
Current Treatment ◽  
Intravitreal Ranibizumab ◽  
Vascular Growth ◽  
Vein Occlusion ◽  
Vascular Growth Factor ◽  
Central Retinal Vein ◽  
Ranibizumab Treatment

The two main complications of central retinal vein occlusion are macular edema and neovascularizations. Intravitreal anti-vascular growth factor and corticosteroid injections are the mainstays of the current treatment of central retinal vein occlusion. In this review, we aimed to summarize the clinical studies of intravitreal ranibizumab in macular edema secondary to central retinal vein occlusion.

Intravitreales Ranibizumab versus isovolämische Hämodilution zur Behandlung des Makulaödems infolge von zentralem retinalem Venenverschluss: Zwölf-Monats-Ergebnisse einer prospektiven, randomisierten, multizentrischen Studie

2015 ◽  
Vol 1 (2) ◽  
pp. 82-83
Keyword(s):  
Macular Edema ◽  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
Multicenter Trial ◽  
Intravitreal Ranibizumab ◽  
Isovolemic Hemodilution ◽  
Vein Occlusion ◽  
Central Retinal Vein

Zielsetzung: Dies ist eine prospektive, randomisierte, multizentrische, prüferinitiierte Studie zur Beurteilung der 12-Monats-Wirksamkeit der isovolämischen Hämodilution (IH) in Kombination mit sofortigen versus späteren intravitrealen Injektionen (IVI) von Ranibizumab 0,5 mg bei der Behandlung des Makulaödems auf dem Boden eines frühen zentralen retinalen Venenverschlusses (ZVV). Methoden: Augen mit nicht mehr als 8 Wochen zuvor aufgetretenem Makulaödem infolge eines ZVV erhielten entweder monatliche Ranibizumab-IVI in Kombination mit IH (Gruppe I; n = 28) oder IH allein (Gruppe II; n = 30). Von Monat 2 bis 12 konnten die Patienten in beiden Gruppen monatlich mit intravitrealem Ranibizumab behandelt werden. Die wichtigsten Zielgrößen waren die Zunahme der Sehschärfe und die Veränderung der zentralen Netzhaut-Dicke laut optischer Kohärenztomografie. Ergebnisse: Nach 12 Monaten zeigten die Augen in Gruppe I eine durchschnittliche Verbesserung um +28,1 (±19,3) Buchstaben, verglichen mit +25,2 (±20,9) Buchstaben in Gruppe II (p = 0,326). Diese Ergebnisse wurden mit einer signifikant geringeren Anzahl Injektionen in Gruppe II erreicht. Zudem benötigten 30% der Augen in Gruppe II über die 12-monatige Studiendauer hinweg gar keine Ranibizumab-IVI. Schlussfolgerung: Die Ranibizumab-IVI zusätzlich zur IH erwiesen sich als hochgradig wirksam in Bezug auf die Verbesserung der Sehschärfe und Reduktion des Makulaödems infolge von ZVV. Eine initiale IH bei frühem ZVV könnte eine erste Therapieoption bei Patienten sein, die gegenüber IVI Vorbehalte haben. Übersetzung aus Kreutzer TC, et al: Intravitreal ranibizumab versus isovolemic hemodilution in the treatment of macular edema secondary to central retinal vein occlusion: twelve-month results of a prospective, randomized, multicenter trial. Ophthalmologica 2015;233:8-17 (DOI: 10.1159/000369566)

INTRAVITREAL RANIBIZUMAB FOR MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION

Retina ◽  
2011 ◽  
Vol 31 (6) ◽  
pp. 1060-1067 ◽  
Author(s):  
Sarah M Risard ◽  
Dante J Pieramici ◽  
Melvin D Rabena ◽  
Jessica C Basefsky ◽  
Robert L Avery ◽  
...  
Keyword(s):  
Macular Edema ◽  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
Intravitreal Ranibizumab ◽  
Vein Occlusion ◽  
Central Retinal Vein

scholarly journals Emerging Therapies for the Treatment of Central Retinal Vein Occlusion and Macular Edema

2019 ◽  
pp. 54-57
Keyword(s):  
Macular Edema ◽  
Laser Treatment ◽  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
Current Treatment ◽  
Vein Occlusion ◽  
Anti Vegf ◽  
Emerging Therapies ◽  
New Applications ◽  
Central Retinal Vein

Many agents are used in the current treatment of central retinal vein occlusion and its complications. These treatments include anti-VEGF agents and steroids. Laser treatment is still up to date. In addition, many treatments are being developed outside the routine are being studied. In this review, treatments and new applications other than anti-VEGF, steroids, and laser used in the treatment of central retinal vein occlusion and macular edema will be reviewed.

scholarly journals Intravitreal Ranibizumab versus Isovolemic Hemodilution in the Treatment of Macular Edema Secondary to Central Retinal Vein Occlusion: Twelve-Month Results of a Prospective, Randomized, Multicenter Trial

2014 ◽  
Vol 233 (1) ◽  
pp. 8-17 ◽  
Author(s):  
Thomas C. Kreutzer ◽  
Armin Wolf ◽  
Martin Dirisamer ◽  
Rupert W. Strauss ◽  
Paul Foerster ◽  
...  
Keyword(s):  
Visual Acuity ◽  
Macular Edema ◽  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
Intravitreal Ranibizumab ◽  
Isovolemic Hemodilution ◽  
Vein Occlusion ◽  
Group I ◽  
Group Ii ◽  
Central Retinal Vein

Purpose: This is a prospective, randomized, multicenter, investigator-initiated trial to evaluate the 12-month effectiveness of isovolemic hemodilution (IH) with prompt versus deferred intravitreal injections (IVI) of ranibizumab 0.5 mg for the treatment of macular edema secondary to early central retinal vein occlusion (CRVO). Methods: Eyes with macular edema due to CRVO having occurred not more than 8 weeks previously received either monthly ranibizumab IVI in combination with IH (group I, n = 28) or IH alone (group II, n = 30). From month 2 to 12, the patients in both groups could be treated with monthly intravitreal ranibizumab. The main outcome variables were gain of visual acuity and the course of central retinal thickness as measured with optical coherence tomography. Results: At 12 months, eyes in group I on average gained +28.1 (±19.3) letters compared to +25.2 (±20.9) letters in group II (p = 0.326). This result was achieved with significantly fewer injections in group II. Additionally, 30% of the eyes in group II did not need ranibizumab IVI during the 12 months of the trial. Conclusion: Ranibizumab IVI in addition to IH proved to be highly effective in increasing visual acuity and reducing macular edema secondary to CRVO. Initial IH in early CRVO may be a first treatment option in patients anxious about IVI.

Sign in / Sign up

Export Citation Format

Share Document